<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>研发客 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-26T07:25:00+08:00</updated>
  <subtitle>《研发客》公众号由上海汐潮信息技术有限公司提供，行业资深中英文独立编辑记者创办。我们观察药物创新生态，报道临床研究与监管科学。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>研发客独家资本市场调研报告+药品注册法规蓝皮书，这里有机会免费拿！</title>
    <updated>2020-12-25T22:51:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-25:/s/yjW-cSpZmOyLPM0Owa-iAA</id>
    <link href="https://mp.weixin.qq.com/s/yjW-cSpZmOyLPM0Owa-iAA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>用糖工程毕赤酵母敲开低成本抗体开发之门｜江湖</title>
    <updated>2020-12-24T22:38:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-24:/s/vCN9PPA7v9js5yaEqdZW7g</id>
    <link href="https://mp.weixin.qq.com/s/vCN9PPA7v9js5yaEqdZW7g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>极目生物获得国内首个治疗UME临床试验批件! 脉络膜上腔给药注射给患者带来更多福音|新闻稿</title>
    <updated>2020-12-24T22:38:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-24:/s/9h6tDffl4F6N7lFWO9zQpQ</id>
    <link href="https://mp.weixin.qq.com/s/9h6tDffl4F6N7lFWO9zQpQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>快来填写研发客资本市场调研问卷</title>
    <updated>2020-12-24T22:38:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-24:/s/n67Kf7I40HaOmULCxXAJpw</id>
    <link href="https://mp.weixin.qq.com/s/n67Kf7I40HaOmULCxXAJpw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>科伦药业从仿到创的战略变化 | DRR专题 · 转型</title>
    <updated>2020-12-24T02:46:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-24:/s/gCLT1jSkuXWIrLCOg4OflA</id>
    <link href="https://mp.weixin.qq.com/s/gCLT1jSkuXWIrLCOg4OflA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020即将翻篇，您对明年有信心吗？快来填写研发客调研问卷</title>
    <updated>2020-12-24T02:46:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-24:/s/DHkjfxr6znt-abdAA4XyMg</id>
    <link href="https://mp.weixin.qq.com/s/DHkjfxr6znt-abdAA4XyMg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新法能否真正保护创新药？| 法规观察</title>
    <updated>2020-12-23T00:39:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-23:/s/3d5-5-yJSlFNFxBqParQ4A</id>
    <link href="https://mp.weixin.qq.com/s/3d5-5-yJSlFNFxBqParQ4A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>创业老兵娄实的新起点 | 遇见</title>
    <updated>2020-12-20T21:31:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-20:/s/hAAiXfDr0_yDovKyDvCpVw</id>
    <link href="https://mp.weixin.qq.com/s/hAAiXfDr0_yDovKyDvCpVw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Bionnova生物医药创新者论坛：速度与安全研讨会回顾 | 新闻稿</title>
    <updated>2020-12-20T21:31:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-20:/s/5qEjvs2u56lZYzbe3a8cwg</id>
    <link href="https://mp.weixin.qq.com/s/5qEjvs2u56lZYzbe3a8cwg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA批准XPOVIO®用于治疗接受过至少一线治疗的多发性骨髓瘤患者 | 新闻稿</title>
    <updated>2020-12-20T21:31:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-20:/s/uxihwzJirAxUYDTAVWmfCA</id>
    <link href="https://mp.weixin.qq.com/s/uxihwzJirAxUYDTAVWmfCA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>为避免利益冲突，SMO和CRO该不该分家｜第一现场</title>
    <updated>2020-12-17T23:14:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-17:/s/_GFUQfD_-fqvQacbRIxfJg</id>
    <link href="https://mp.weixin.qq.com/s/_GFUQfD_-fqvQacbRIxfJg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>NMPA正式受理HLX01（利妥昔单抗）类风湿关节炎新适应症的上市注册申请 | 新闻稿</title>
    <updated>2020-12-17T23:14:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-17:/s/b1A-c-3L6l6gsBSYhgytXQ</id>
    <link href="https://mp.weixin.qq.com/s/b1A-c-3L6l6gsBSYhgytXQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医药板块进入周期性调整 | 投资观察</title>
    <updated>2020-12-15T23:29:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-15:/s/E95Nw8CfXJoKzdgau8VtFQ</id>
    <link href="https://mp.weixin.qq.com/s/E95Nw8CfXJoKzdgau8VtFQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>瓴路药业宣告成立：与全球领先生物制药公司战略合作，为亚洲和全球患者提供创新药物 | 新闻稿</title>
    <updated>2020-12-15T23:29:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-15:/s/lwqQWPF7bmkniyLYFfeKfQ</id>
    <link href="https://mp.weixin.qq.com/s/lwqQWPF7bmkniyLYFfeKfQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>骨髓瘤治疗新进展：Selinexor（ATG-010）三种治疗方案入选最新版NCCN®多发性骨髓瘤诊疗指南 | 新闻稿</title>
    <updated>2020-12-15T23:29:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-15:/s/svKt9fvLJmZI1kCUBWimEQ</id>
    <link href="https://mp.weixin.qq.com/s/svKt9fvLJmZI1kCUBWimEQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020即将翻篇，您对明年有信心吗？快来填写研发客调研问卷</title>
    <updated>2020-12-14T22:51:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/ISy-NIStNLARdtylbFytbg</id>
    <link href="https://mp.weixin.qq.com/s/ISy-NIStNLARdtylbFytbg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第二届“CSCO-再鼎临床肿瘤新进展高峰论坛”召开 | 新闻稿</title>
    <updated>2020-12-14T22:51:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/trKBjd6_IHCnSc6CCjRR8g</id>
    <link href="https://mp.weixin.qq.com/s/trKBjd6_IHCnSc6CCjRR8g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>罕见病的中国桥梁 | 江湖</title>
    <updated>2020-12-13T22:15:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-13:/s/iAzaB8y3itzHHRxOki7JsA</id>
    <link href="https://mp.weixin.qq.com/s/iAzaB8y3itzHHRxOki7JsA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>PD-1耐药后TLR7/8激动剂能否带来转机｜边研</title>
    <updated>2020-12-11T22:51:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/E9ExQvWmZDLrvR9xHyYH-Q</id>
    <link href="https://mp.weixin.qq.com/s/E9ExQvWmZDLrvR9xHyYH-Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>